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Abstract
Antioxidant phytochemicals are investigated as novel treatments for supportive therapy in b-thalassemia. The dietary
indicaxanthin was assessed for its protective effects on human b-thalassemic RBCs submitted in vitro to oxidative haemolysis
by cumene hydroperoxide. Indicaxanthin at 1.0–10mM enhanced the resistance to haemolysis dose-dependently. In addition,
it prevented lipid and haemoglobin (Hb) oxidation, and retarded vitamin E and GSH depletion. After ex vivo spiking of blood
from thalassemia patients with indicaxanthin, the phytochemical was recovered in the soluble cell compartment of the RBCs.
A spectrophotometric study showed that indicaxanthin can reduce perferryl-Hb generated in solution from met-Hb and
hydrogen peroxide (H2O2), more effectively than either Trolox or vitamin C.
Collectively our results demonstrate that indicaxanthin can be incorporated into the redox machinery of b-thalassemic RBC
and defend the cell from oxidation, possibly interfering with perferryl-Hb, a reactive intermediate in the hydroperoxide-
dependent Hb degradation. Opportunities of therapeutic interest for b-thalassemia may be considered.
Keywords: Antioxidants, betalains, haemoglobin, indicaxanthin, phytochemicals, red blood cells
Introduction
Beta-thalassemia is a genetic haemolytic disorder
characterised by an increased generation of reactive
oxygen species, first caused by haemoglobin (Hb)
auto-oxidation and precipitation [1,2]. This is
associated to depletion of the red blood cell (RBC)
antioxidant defence, which results in damage to cell
components, impairment of morphology and function
of cell membrane and accelerated RBC destruction
[2–6]. In addition, the transfusion therapy, which is
the standard treatment for these patients, generates a
state of iron overload that further affects the oxidative
status [7]. Although early studies had shown that
supplementation with antioxidant vitamins did not
cause substantial benefit in the requirement of
transfusions nor in the Hb levels [8], recent evidence
has been provided that it may be of help to
b-thalassemia patients [9,10]. It has been observed
that administration of vitamin E improves the
antioxidant/oxidant balance in plasma, and counter-
acts the oxidative processes in erythrocytes, thus
contributing to their longevity. In addition, natural
antioxidants such as rutin [11], curcumin, and the tea
polyphenols [12], have recently been shown to have
salutary effects on thalassemic erythrocytes [13],
suggesting that phytochemicals, possibly used in
combination with vitamin E and/or iron chelators,
may offer new co-therapeutic opportunities.
Betalains, nitrogen eterocycles the redox properties
of which have been reported in a number of in vitro
studies [14–18], recently emerged as another class of
phytochemicals to be considered as potential natural
antioxidants. Among them, the betaxanthin indica-
xanthin, the yellow pigment of the cactus pear fruit,
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is an immonium conjugate of proline with betalamic
acid (Figure 1). A number of investigations have
shown the radical-scavenging activity of this com-
pound in either aqueous or hydrophobic environ-
ments [17,19]. Studies with humans showed that
dietary indicaxanthin is highly bioavailable, and
attains a peak plasma concentration of 2.2mg/ml
(7mM) after ingestion of a fruit meal containing 28 mg
[20]. In addition, in parallel with its plasma
concentrations, it can distribute in body compart-
ments such as low density lipoproteins and RBCs
[20,21].
This study investigated the activity of indicaxanthin
in RBCs from b-thalassemia patients challenged
in vitro with cumene hydroperoxide (cumOOH), an
organic compound promoting a sequel of oxidative
events mimicking the pathophysiological pathway
leading these cells to haemolysis. A number of
measurements, including the resistance to haemolysis,
evaluation of oxidation products from lipids and Hb,
and relationships with the major cell antioxidants such
as GSH and vitamin E, were performed to assess
antioxidative effects of the phytochemical. Additional
experiments in solution aimed at studying the reaction
of indicaxanthin with perferryl-Hb, a hypervalent-iron
highly reactive species, were carried out to have
insights into mechanisms involved in the cytoprotec-
tive effects.
Methods
Chemicals
Ascorbic acid, bovine met-Hb, butylated hydroxy-
toluene (BHT), cumOOH, 5,50-dithiobis(2-nitro
benzoic acid) (DTNB), ethylendiaminetetraacetic
acid (EDTA), hemin, hydrogen peroxide (H2O2),
tetraethoxypropane (TEP), thiobarbituric acid (TBA),
a-tocopherol and Trolox, were from Sigma (St Louis,
MO). All other chemicals were of research highest
purity grade. Ion-free water and buffers used through-
out this study were filtered through Chelex-100
(Sigma), and suitable plastic labware was used to
avoid the effect of adventitious metals.
Isolation of indicaxanthin
Indicaxanthin was isolated from cactus pear (Opuntia
ficus-indica) fruits (yellow cultivar). The phytochem-
ical was separated from the methanolic extract of the
pulp by liquid chromatography on Sephadex G-25
[17]. Fractions containing the pigment were sub-
mitted to cryoessiccation. The essiccated material was
re-suspended in 1% acetic acid in water [22] and
submitted to semi-preparative HPLC using a Varian
Pursuit C18 column (250 £ 10 mm i.d.; 5mm;
Varian, Palo Alto, CA), eluted with a 20 min linear
gradient elution from solvent A (1% acetic acid in
water) to 20% solvent B (1% acetic acid in
acetonitrile) with a flow of 3 ml/min [17]. Spectro-
photometric revelation was at 482 nm. The elution
volumes relevant to indicaxanthin were collected.
Samples after cryoessiccation were re-suspended in
PBS at a suitable concentration.
Red blood cells
Blood samples from b-thalassemia intermedia patients
(n ¼ 15), previously characterized for b-globin gene
mutation, were obtained from the patients by
venipuncture, with informed consent. With the
exception of 5 patients, who had never been
transfused, they had received blood transfusions at
least 2 years before this study. The mean value of Hb
was 12.5 ^ 1.8 mM (per heme group). EDTA
(1 mg/ml blood) was used as an anticoagulant. RBCs
were sedimented at 1000g for 10 min and washed
three times with phosphate saline buffer (PBS),
pH 7.4. Similarly, RBCs were obtained from
blood samples of healthy volunteers (n ¼ 9). The
cells were suspended in PBS, to obtain a suitable
hematocrit (HT).
Oxidative hemolysis
RBC oxidation was carried out by incubating RBC
suspensions (HT 1%) with 300mM cumOOH at
378C, in the absence or in the presence of
indicaxanthin. CumOOH was added to the erythro-
cyte suspensions as ethanol solution. The volume
added never exceeded 0.5% of the total incubation
volume. The extent of the time-dependent haemolysis
was determined as follows. A volume (0.2 ml) of the
incubation mixture at any given incubation time was
diluted with 10 volumes of PBS and centrifuged at
1000g for 10 min to precipitate the cells. The
absorbance of the supernatant was then evaluated at
540 nm. Similarly, a volume of the same incubation
mixture was treated with 10 volumes of 5 mM sodium
phosphate buffer, pH 7.4 (hypotonic buffer) and
Figure 1. Molecular structure of indicaxanthin.
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8 briefly exposed to an ultrasonic bath to yield complete
haemolysis. After a centrifugation at 1000g for 10 min
the absorbance of the supernatant was evaluated at
540 nm. The percentage of haemolysis was calculated
from the ratio of the absorbances.
Consumption of indicaxanthin
Indicaxanthin was extracted from 1 ml oxidation
mixture with three volume of chloroform/methanol
(2:1, v/v). The methanol phase was dried under
nitrogen, re-suspended in 1% acetic acid in water, and
analysed on a Varian Microsorb C-18 column
(250 £ 4.6 mm i.d., 5mm), eluted with the same
gradient reported above, with a flow of 1.5 ml/min.
Spectrophotometric revelation was at 482 nm. Quan-
titation of indicaxanthin was by reference to standard
curves constructed with 5–100 ng of the purified
compound, and by relating the amount of the
compound under analysis to the peak area.
Measurement of vitamin E and GSH
Vitamin E was measured in RBCs (HT 1%, 5 ml)
collected at 1000g for 10 min. The cell pellet was
re-suspended with 1 ml of PBS, and mixed with two
volumes of absolute ethanol, followed by two
successive extractions with six and two volumes of
petroleum ether. The organic extracts were gathered,
dried under a nitrogen stream, resuspended in
several microliters of methanol, and vitamin E was
separated by HPLC using a Supelco SupelcosilTM
(Bellefonte, PA) LC-18 column (0.46 £ 25 cm).
The eluent was methanol with a flow rate of
1.0 ml min21 [20]. Fluorometric detection was with
excitation at 290 nm and emission at 335 nm.
Quantitation was by reference to standard curves
constructed with 5–100 ng of a-tocopherol, and by
relating the amount of the compound under analysis
to the peak area.
Intracellular GSH was determined by titration with
DTNB. Briefly, RBCs (HT 1%, 3 ml) were collected
by centrifugation at 1000g for 10 min, then 0.5 ml of
H2O were added to the RBC pellet to lyse the cells.
Proteins were precipitated by addition of 0.5 ml of a
metaphosphoric acid solution (1.67 g metaphosphoric
acid, 0.20 g EDTA and 30 g NaCl in 100 ml of H2O).
After centrifugation at 3000g for 10 min, 400ml of the
clear supernatant were combined with 500ml of
300 mM Na2HPO4, pH 8.0, and the absorbance at
412 nm was read against a blank consisting of 400ml
of supernatant and 500ml of H2O. Then, 100ml of
DTNB solution (20 mg DTNB in 100 ml of 1%
sodium citrate) were added to both blank and sample,
and the absorbance of the sample was read against the
blank at 412 nm, after 5 min at 378C in a thermostatic
cuvette to allow color development. Under these
conditions the molar extinction coefficient of GSH is
13,600 [23].
Measurement of lipid oxidation
The conjugated dienes (CD) lipid hydroperoxides
were extracted from 2.0 ml of RBC suspension (HT
2%), with 6.0 ml chloroform/methanol (2:1, v:v). The
organic extract was dried under nitrogen, re-
suspended in cyclohexane and quantitated spectro-
photometrically at 234 nm, using a molar absorption
coefficient of 27,000 [24].
MDA was measured in RBCs (HT 1%, 0.5 ml)
mixed with 1.5 ml H2O, 5ml of 40 mM BHT and 5ml
of 1 M NaOH. After cell homogenization, 250ml of
0.6% TBA in 35% HClO4 were added and the
suspension heated for 60 min. Then, samples were
cooled, centrifuged at 1000g for 10 min, and the
MDA–TBA adduct in the supernatant was separated
by isocratic HPLC, using a Supelco Supelcosil LC-18
column (0.46 £ 25 cm) (Bellafonte, PA). Eluent was
40% methanol in 50 mM potassium phosphate
buffer, pH 6.8, at 1.5 ml min21. The MDA–TBA
adduct was revealed spectrophotometrically at
532 nm and quantified by reference to a calibration
curve of TEP submitted to the TBA colorimetric
procedure.
Measurement of haemoglobin and hemin
RBCs (HT 1%, 1 ml) were collected by centri-
fugation, and the cell pellet, re-suspended in 2.0 ml of
hypotonic buffer, was briefly exposed to an ultrasonic
bath to yield complete haemolysis. After centri-
fugation, aliquots of supernatant were scanned at
500–700 nm, and concentrations of the oxidation
products of Hb in mixtures of HbO2, met-Hb and
hemichrome were calculated according to Winter-
bourn [25], and expressed per heme group. The
amount of hemin associated with RBC membranes
was measured in the membrane pellet re-suspended in
1% SDS in PBS, by spectrophotometry at 408 nm.
Concentrations were evaluated from a calibration
curve of 2–10mM hemin in the same SDS buffer.
Ex vivo spiking of blood from b-thalassemic patients
with indicaxanthin and binding to red blood cells
Blood from each b-thalassemia patient was incubated
at 378C, for 15 min, in the presence of PBS solutions
of indicaxanthin, to obtain final concentrations of
5.0–50mM. RBCs were isolated by centrifugation,
washed and re-suspended in PBS to obtain a 10%
hematocrit. Aliquots (7.5 ml) were extracted with 3
volumes of chloroform/methanol (2:1, v:v), the
methanol phase was dried and re-suspended in 1%
acetic acid in water, then indicaxanthin was measured
by HPLC as above reported.
Cytoprotective effects of phytochemical indicaxanthin 755
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8 In other experiments, RBCs isolated after spiking of
plasma with 25mM indicaxanthin were re-suspended
in hypotonic buffer to obtain a 10% hematocrit and
briefly exposed to an ultrasonic bath to achieve
complete haemolysis. Membrane were precipitated by
centrifugation (100,000g for 1 h, at 48C), and re-
suspended with hypotonic PBS. Either membrane or
supernatant preparations were extracted and analysed
for indicaxanthin.
Reaction of indicaxanthin with hypervalent-iron
Hb species
Bovine met-Hb (100mM) in PBS was oxidized to
perferryl-Hb (zHb[FeIVvO]) by 100mM H2O2, at
378C, either in the absence or in the presence of
25mM either indicaxanthin or other antioxidants.
The reaction was carried out in a Beckman DU 640
UV/vis spectrophotometer, equipped with a tempera-
ture controller. Spectrophotometric scans were
monitored at 500–700 nm [26] and the concen-
trations of the oxoferryl species was calculated from
the absorbance at 556 nm, the point at which met-
and ferryl-forms differ most (D ¼ 3.6 mM cm21)
[11]. The absorption spectrum of indicaxanthin,
from 360 to 500 nm with a maximum at 482 nm [27],
did not interfere with the spectrophotometric
measurements of the Hb species.
Results
The oxidative state of the b-thalassemic RBCs was
first assessed in terms of cell antioxidants, and level of
oxidation products from lipids and haemoglobin in the
soluble cell fraction and in membrane. The results are
reported in Table I in comparison with healthy RBCs.
Vitamin E and GSH were remarkably reduced in the
pathological RBCs, whereas, substantial amounts of
CD lipid hydroperoxides and MDA, and of oxidised
products from Hb, including met-Hb, hemichrome,
and hemin in the membrane, were found. Because
of the wide spectrum of disease severity, inter-
individual differences of the redox conditions of the
RBCs are expected. As a consequence, the coefficient
of variation of the data from thalassemia cells is quite
high with respect to healthy RBCs.
Cumene hydroperoxide is a lipophilic oxidant
requiring iron to promote radical production and
start a cascade of events including oxidation of
membrane components and degradation of haemo-
globin. Because of the limited antioxidant defence and
higher amounts of hemin in membrane, thalassemic
RBCs were more susceptible than healthy RBCs to the
cumOOH-induced oxidative haemolysis, and a com-
plete cytolysis was evident when only 20% of healthy
RBCs were broken. In addition, in accordance with
the wide variability of the cell redox conditions, the
kinetic curve of haemolysis showed a slow progression
and did not exhibit a definite time of resistance
(Figure 2(a)). When added to the incubation mixture
at concentrations ranging from 1 to 10mM, indi-
caxanthin enhanced the resistance of RBCs to
haemolysis in a concentration-dependent manner
(Figure 2(b)). The phytochemical appeared to be
totally consumed during the RBC oxidation
(Figure 2(b)).
GSH and vitamin E were rapidly exhausted after
oxidation of thalassemic RBCs with cumOOH. Co-
incubation of the cells with 1–10mM indicaxanthin
resulted in a decreased rate of consumption of both
antioxidants, the higher the concentration the slower
the consumption (Figure 3(a) and (b)).
A rapid accumulation of MDA, hemichrome and
hemin in the membrane (Figure 4) was evident in the
cumOOH-treated thalassemic RBCs. Indicaxanthin
delayed MDA formation, and inhibited the formation
of Hb degradation products, with the effect being
related to the concentration added (Figure 4).
Binding of indicaxanthin to thalassemic erythro-
cytes and cell location were investigated. Ex vivo
spiking of blood from thalassemia patients with
indicaxanthin, in the range of 5.0–50.0mM, resulted
in the incorporation of increasing amounts of the
compound, with a maximum amount of 1.03 ^
0.1 nmoles/ml packed RBCs, at 25mM (Figure 5).
When researched in either membrane or soluble cell
preparations, indicaxanthin was found entirely associ-
ated with the aqueous cell compartment.
Table I. Major antioxidants and oxidised products from lipids and Hb in RBCs from b thalassemia patients and healthy volunteers.
b-thalassemic RBCs, n ¼ 15 c.v. (%) Healthy RBCs, n ¼ 9 c.v. (%)
Vitamin E (mM) 0.80 ^ 0.19* 23.7 1.9 ^ 0.15 7.8
GSH (mM) 0.85 ^ 0.25* 29.4 2.21 ^ 0.2 9.0
CD-lipid hydroperoxides (mM) 210 ^ 41* 19.5 91 ^ 8 8.8
MDA (mM) 12 ^ 2.7* 22.5 1.5 ^ 0.18 12.0
Met-Hb (mM)† 1.6 ^ 0.35* 21.8 0.8 ^ 00.9 11.2
Hemicrome (mM)† 22 ^ 4 18.1 n.d.
Hemin (mM) 0.21 ^ 0.05 23.8 n.d.
Values are the mean ^ S.D. of n separate determinations. c.v., coefficient of variation (S.D. £ 100%); n.d., not detectable.
* Significantly different from healthy RBCs, P , 0.0001 (Student’s-t test);
† Concentration was expressed per heme group.
L. Tesoriere et al.756
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Reaction of indicaxanthin with hypervalent-iron
Hb species
The hydroperoxide-mediated degradation of heme-
proteins, including Hb, proceeds through the transient
formation of highly reactive radical species.
The primary oxidation of the heme iron of oxy-Hb to
met-Hb is followed by the formation of perferryl-Hb
[28–30]. This species, two oxidation equivalents
above the met-Hb, includes a hypervalent-iron
oxoferryl heme group [FeIVvO] detected spectro-
photometrically [28,29,31], and a radical species
localized on the gobin [29,32]. Decay of the radical
to the oxoferryl form [26], followed by slow auto-
reduction to met-Hb, involves intramolecular electron
transfer and modification of the globin moiety [28,29].
Experiments in solution were designed to check
whether indicaxanthin would reduce perferryl-Hb.
Purified met-Hb was treated with H2O2 to generate
perferryl-Hb, either in the absence or in the presence
of indicaxanthin, and the reaction monitored by the
spectral changes between 500 and 700 nm. When
100mM met-Hb and 100mM H2O2 were incubated at
378C, the characteristic peak of met-Hb at 630 nm
(Figure 6, dotted line) was almost completely lost,
while two new peaks at 545 and 580 nm, characteristic
of the oxoferryl moiety, appeared (Figure 6, line 1).
The amount of oxoferryl after a 1-min incubation was
calculated as 50 ^ 4mM (n ¼ 10) from the changes
in the absorption at 556 nm. Spontaneous reduction
Figure 2. (a) CumOOH-induced haemolysis of healthy (open symbols) and thalassemic RBCs (full symbols); (b) effect of 1–10mM
indicaxanthin on the cumOOH-induced haemolysis of thalassemic RBCs and time course of the consumption of 10mM indicaxanthin
(dotted line).
Figure 3. CumOOH-induced GSH (a) and vitamin E (b)
consumption in thalassemic RBCs incubated in the absence (open
symbols) or in the presence (full symbols) of 1–10mM
indicaxanthin.
Cytoprotective effects of phytochemical indicaxanthin 757
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of the oxoferryl moiety started soon after 1 min,
however, because of the globin denaturation, the
spectrophotometric trace of met-Hb after 20 min did
not overlap the original met-Hb spectrum (not
shown). When 25mM indicaxanthin was added to
the incubation mixture before the oxidant (Figure 6,
line 2), the amount of oxoferryl moiety after 1 min was
10 ^ 1mM (n ¼ 8). Furthermore, the spectrum
recorded after 3 min entirely fitted the original met-
Hb spectrum (Figure 6, line 3). A reduction rate of the
perferryl species of 660 ^ 50 nM s21 was calculated
from the spectrophotometric data collected within the
first minute. As a comparison, antioxidants known to
reduce perferryl moieties were assayed [33–35].
Trolox, the water-soluble analog of vitamin E and
vitamin C, at 25mM, reduced the perferryl-Hb at a
rate of 66 ^ 5.7 and 83 ^ 7.9 nM s21, respectively.
Discussion
The sequel of events consequent to the precipitation
of Hb a-chains remarkably affects the redox status of
b-thalassemia RBCs. Indeed, depletion of the main
cell antioxidants, and accumulation of products from
oxidised lipids and Hb, have been observed in RBCs
from thalassemia patients in the present as well as in
previous studies [7,36]. This paper shows that
indicaxanthin, a dietary phytochemical whose redu-
cing and antioxidant properties [17,19], as well as
bioavailability in humans [20] have recently been
reported, has cytoprotective activity in b-thalassemia
RBCs submitted to an oxidative injury in vitro.
A cascade of oxidative reactions, that mimick and
accelerate the pathophysiologic events leading thalas-
semic RBCs to haemolysis, is triggered by treatment
Figure 4. CumOOH-induced formation of MDA (a), hemichrome
(b) and hemin (c) in thalassemic RBCs incubated in the absence
(open symbols) or in the presence (full symbols) of 1–10mM
indicaxanthin.
Figure 5. Incorporation of indicaxanthin in thalassemic RBCs
following ex vivo spiking of blood with the purified compound.
Figure 6. Spectral changes of perferryl-Hb upon reaction with
indicaxanthin. Met-Hb (100mM; dotted line) was converted to
perferryl-Hb by a 1 min incubation with H2O2 (100mM; line 1).
Indicaxanthin (25mM) was added to the incubation mixture before
H2O2 and scans were taken at 1 (line 2) and 3 (line 3) min of
incubation.
L. Tesoriere et al.758
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membrane cell compartment [37]. In the presence of
redox-active iron and membrane-adhering Hb,
cumOOH generates H2O2, met-Hb and a number of
cumOOH-derived oxyradicals starting oxidation of
membrane lipids [38]. Further oxidation of met-Hb
by hydroperoxides, results in formation of hemi-
chrome followed by precipitation of hemin, which is
crucial to the membrane damage ensuing in haemo-
lysis [39–42]. Indeed, the rate of formation of these
products determines the rate of haemolysis [1].
Our work shows that indicaxanthin is capable of
enhancing dose-dependently the resistance of thalas-
semic RBCs to the cumOOH-induced haemolysis, by
preventing oxidation of both membrane and soluble
cell components. Indicaxanthin has been shown to be
incorporated in human healthy erythrocytes in vivo
[20] and ex vivo [21]. As a result of oxidative
modifications and cross-linking of lipid and protein
components, thalassemia RBCs have an altered
membrane morphology, including phospholipid
asymmetry [43,44], and dysfunction of transport
systems [45]. This study provides evidence that
spiking of blood from thalassemia patients with
indicaxanthin is followed by its incorporation in the
RBCs, indicating that the pathological alterations do
not affect a trans-bilayer movement of this phyto-
chemical. In addition, the incorporated amount is
quite comparable with that measured in RBCs from
healthy volunteers after spiking of blood under
conditions similar to those of the present work [21].
Indicaxanthin has been recovered in the aqueous
compartment of thalassemia cells. Though it is water-
soluble, indicaxanthin has appeared capable of binding
to lipid moieties such as LDL [19,20], while other
results from our laboratory indicate a preferential
distribution of indicaxanthin at the bilayer/water
interface in a dipalmitoyl phosphatidylcholine lipo-
somal system (manuscript in preparation). The
evidence that indicaxanthin is cell-permeating is
consistent with an amphiphilic character of the
molecule, which may be crucial to locate the
compound in the cell, possibly at the water–lipid
interface. This could eventually allow interactions with
aqueous, as well as with lipid-derived radicals floating
to the lipid–water interface [46].
Scavenging of lipoperoxyl radicals by indicaxanthin,
has been reported [19]. Such an activity could account
for the observed decrease of MDA production as well
as of vitamin E consumption, but cannot entirely
explain the anti-haemolytic effects [47,48].
The net decrease of the cumOOH-induced hemin
and hemichrome production provided evidence that
indicaxanthin effectively prevented Hb degradation,
an autoxidation process involving the intermediate
formation of the highly reactive perferryl-Hb, a species
that comprises a radical localised on the globin,
possibly an aromatic amino acid radical [29,32,49],
and an oxoferryl heme group [28,29,31]. Our
spectrophotometric measurements in solution showed
that indicaxanthin is highly effective in reducing
perferryl-Hb generated from met-Hb and H2O2,
inducing a quite rapid reduction of the hypervalent-
iron, and producing met-Hb. Whether reduction by
indicaxanthin may occur at the oxoferryl moiety or the
unpaired electron electrophile center at the globin
moiety, or both, is indistinguishable by the spectro-
photometric evidence. It is noteworthy that the
spectrum of met-Hb induced by indicaxanthin
entirely fitted the spectrum of native met-Hb. While
indicating reaction with the oxoferryl moiety, this also
suggests that a reduction of the globin radical occurs,
otherwise the oxidation of globin residues by perferryl-
Hb would make the met- to ferryl-Hb transformation
irreversible [50].
On a molar basis, the reducing activity of
indicaxanthin towards perferryl-Hb was one order of
magnitude higher than that exhibited by effective
reductants of perferryl-Hb such as ascorbate [35] or
Trolox [33,34]. In accordance with these results,
recent work showed that the hypervalent-iron por-
phyrin moieties of either compound I or II, formed
during the catalytic cycle of the human heme-enzyme
myeloperoxidase [51], can be reduced by this
phytochemical [52], with calculated rate constants of
the order of 106 and 105 M21 s21, respectively,
whereas, vitamin C exhibits rate constants of the
order of 105 and 103 M21 s21 for the reduction of the
same intermediates [53]. Then indicaxanthin seems to
be highly effective in reducing protein-bound hyper-
valent-iron heme species. This suggests that the
observed cytoprotective effects in thalassemia red
blood cells could be accounted for by the inhibition of
the autoxidative chain reaction of Hb. Prevention of
this self-amplifying oxidation process is consistent
with the minute amounts of indicaxanthin required to
delay cell lysis. In addition, protection of haemoglobin
would in turn spare GSH, a major RBC component to
regulate cell redox environment and counteract Hb
oxidation [54,55]. Finally, the deleterious reactions
triggered by precipitation of Hb, including heme-iron-
induced lipid peroxidation [56–58], would also be
delayed.
The redox properties and radical-scavenging
activity of indicaxanthin have been proved by a
number of assays [14–19], however, the molecular
mechanism is still unknown. It is accepted that the
conjugated p-orbitals of indicaxanthin are responsible
for the reducing properties of the molecule
[14,15,17]. Though the withdrawal of an electron
may be hindered by the positive charge present in the
nitrogen atom, a neutral pH, by stabilizing a
deprotonated species, may favour oxidation of the
molecule, leading to a delocalised betalain radical.
Regeneration from its radical, would remarkably
amplify the molecule effectiveness, and has been
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8 discussed to explain the protective activity of
indicaxanthin in a low-density lipoprotein oxidation
model [19]. In the present study, the time-course of
consumption of indicaxanthin seems to indicate other
fate of indicaxanthin after the oxidative challenges.
The conditions applied and/or the nature of the
radicals generated apparently make the oxidation of
indicaxanthin a rapid and irreversible process.
Isolation and identification of the product(s) in simple
oxidation models will be of valuable help to shed light
in the redox chemistry of indicaxanthin.
In conclusion, indicaxanthin may be incorporated
in the redox machinery of beta-thalassemic RBCs,
remarkably improving their antioxidant potential. It
seems noticeable that protective effects are evident at
concentrations consistent with the plasma concen-
trations achieved in humans by ingestion of dietary
indicaxanthin [20]. In view of the absence of toxicity
of indicaxanthin [59] and of its potential antioxidative
effects in humans [20,21], present data emphasize the
potential interest of this molecule in the supportive
therapy of thalassemia, while stimulating further
studies involving patients.
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